About Dynacure Company

Dynacure SA is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. The company is developing DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein for the treatment of Myotubular and Centronuclear Myopathies, in strategic collaboration with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other rare disorders, including its DYN201 program for the treatment of Hereditary Spastic Paraplegias caused by mutations in the SPG11 gene.